Trastuzumab-qyyp - Biologic Drug Details

Summary for trastuzumab-qyyp

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for trastuzumab-qyyp

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for trastuzumab-qyyp Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for trastuzumab-qyyp Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for trastuzumab-qyyp Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Trastuzumab-qyyp

Last updated: February 21, 2026

What is Trastuzumab-qyyp?

Trastuzumab-qyyp is a biosimilar to the original biologic trastuzumab, used to treat HER2-positive breast and gastric cancers. Approved by the FDA in December 2022, it is marketed under the name Kanjinti (by AstraZeneca) or as a biosimilar product under different regional names. It is designed to offer a lower-cost alternative to the originator drug, Herceptin.

Market Landscape for HER2-Targeted Therapies

Original Product and Biosimilar Competition

Product Name	Manufacturer	Approval Year	Indications	Price (Estimated)	Market Share (2023)
Herceptin (trastuzumab)	Genentech (Roche)	1998	Breast, gastric	$70,000/year (US)	70% of HER2 therapy market
Trastuzumab-qyyp	AstraZeneca	2022	Breast, gastric	30-50% discount	20% of HER2 biosimilar segment
Other biosimilars	Multiple	2022–2023	Same	Variable	Remaining share

The biosimilar market for trastuzumab intensified after patent expiry in 2018, with multiple biosimilars launched globally. Trastuzumab-qyyp entered a competitive space, capturing part of the biosimilar segment.

Market Penetration and Adoption

Commercialization success depends on:

• Cost savings for payers and providers
• Physician confidence in biosimilar efficacy and safety
• Regulatory policies favoring biosimilar use

In regions with aggressive biosimilar policies (e.g., Europe, Japan), adoption rates exceeded 50% within 2 years of approval[^1].

Pricing and Revenue Projections

Pricing Dynamics

• Originator trastuzumab (Herceptin): $70,000–$75,000/year in the US
• Biosimilar trastuzumab-qyyp: pricing is 30–50% lower, averaging $35,000–$45,000/year

Revenue Models

Assuming:

• 2022 US trastuzumab prescriptions: 300,000 courses
• Biosimilar uptake: 20% in 2023, growing by 10% annually

Year	Prescriptions (biosimilar)	Revenue (biosimilar)	Revenue Loss (vs. original)
2023	60,000	$2.7 billion (at $45,000)	$3.3 billion (initial)
2024	90,000	$4.05 billion	$6.45 billion
2025	120,000	$5.4 billion	$9.6 billion

Projected revenue reduction for Roche’s Herceptin correlates with biosimilar market share increases.

Competitive and Regulatory Influences

Regional Policies

• United States: CMS' increased use of biosimilars in Medicare reduces drug costs; FDA offers 351(k) pathways for biosimilars.
• Europe: directives encourage biosimilar substitution; some countries mandate switching after initial treatment.
• Asia-Pacific: market growth is driven by expanding healthcare budgets, especially in China and India.

Patent Litigation and Market Entry

Patent litigations delayed biosimilar launches in some markets until 2022. Patent expirations for the original trastuzumab in the US occurred mainly in 2018–2019, opening markets for biosimilars including trastuzumab-qyyp.

Key Drivers for Adoption

• Cost savings: payers prefer biosimilars due to lower acquisition costs.
• Physician confidence: increased through clinical data demonstrating bioequivalence.
• Policy support: mandates, tender systems, and formulary preferences.

Financial and Market Outlook

Revenue Trajectory

Biosimilars are expected to account for approximately 60–70% of trastuzumab prescriptions by 2025 in mature markets, depending on regional policies and physician preference. Revenue from trastuzumab-qyyp likely peaks around 2025–2026 at a fraction (10–15%) of the original sales, due to market saturation and entry of competitors.

Future Trends

• Price erosion: biosimilar prices will continue to decline, pressuring revenue.
• Increased biosimilar uptake: driven by policy shifts, especially in Europe and Asia.
• Market expansion: emerging markets will contribute significantly due to growing cancer prevalence and healthcare improvements.

R&D and Portfolio Implications

Pharmaceutical firms will incorporate biosimilars like trastuzumab-qyyp into broader oncology portfolios, leveraging cost advantages while investing in personalized medicine and novel therapeutics.

Key Takeaways

• Trastuzumab-qyyp is a marketed biosimilar to trastuzumab, approved in 2022.
• The biosimilar market growth is driven by lower prices, regulatory support, and healthcare policies.
• Revenue from trastuzumab-qyyp is projected to contribute significantly to biosimilar sales, but will plateau as market saturation occurs.
• Competition remains stiff, with multiple biosimilars and originator brand efforts to maintain market share.
• Regional policies significantly influence adoption rates and revenues.

FAQs

1. How does trastuzumab-qyyp compare to the original trastuzumab in terms of efficacy?
Regulatory agencies require biosimilars like trastuzumab-qyyp to demonstrate bioequivalence and similar safety profiles to the originator. Clinical trials confirm comparable efficacy in approved indications.

2. What are the main factors influencing biosimilar adoption in 2023?
Cost savings, regulatory policies, physician confidence, and hospital tender practices drive adoption.

3. Which regions are leading in biosimilar market penetration for trastuzumab?
Europe and Japan lead in biosimilar utilization, followed by the US. Emerging markets in China and India show rapid growth potential.

4. How might patent expirations affect future revenues for Roche's Herceptin?
Patent expirations in key markets opened the market for biosimilars, decreasing originator sales and pressuring revenues unless Roche secures new indications or formulations.

5. What trends could influence the biosimilar market beyond 2025?
Policy shifts toward mandated switching, improvements in biosimilar manufacturing, and development of newer HER2-targeted treatments will shape future dynamics.

---

References

[1] European Medicines Agency. (2022). Market authorization of biosimilars. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilarity